West Paces Advisors’s Avanos Medical AVNS Stock Holding History

West Paces Advisors’s Portfolio AVNS Stock Details AVNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-1	Closed	-$39	–	476
2017 Q2	$39	Hold	1	–	–	﹤0.01%	507
2017 Q1	$38	Hold	1	–	–	﹤0.01%	505
2016 Q4	$37	Buy	+1	New	+$36	﹤0.01%	554

Other funds holding AVNS

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

West Paces Advisors's AVNS Position: Q3 2017 in Review

West Paces Advisors sold out of Avanos Medical (AVNS) in Q3 2017, closing a stake of 1 share — an estimated $39 sold.

West Paces Advisors first reported a position in AVNS in Q4 2016 and held it in 3 quarters. The position peaked at $39 in Q2 2017. 318 funds tracked by Wall St. Rank hold AVNS as of Q3 2017.

West Paces Advisors reported no remaining Avanos Medical position as of Q3 2017 after selling out during the quarter.
West Paces Advisors sold 1 Avanos Medical share in Q3 2017, an estimated $39.
West Paces Advisors first reported a position in Avanos Medical in Q4 2016 and held it in 3 quarters.
West Paces Advisors's Avanos Medical position peaked at $39 in Q2 2017.
318 funds tracked by Wall St. Rank held Avanos Medical as of Q3 2017.

Based on West Paces Advisors's 13F filing for Q3 2017, filed 22 Dec 2023.